Dr. Stephanie Schonewald counsels biotech and pharmaceutical companies on the strategic development of patent portfolios, patent prosecution, and post-grant patent challenges. She advises clients on a broad range of patent matters, including patent portfolio management and counseling, with particular experience in cell therapies, microbiome therapeutics, gene therapies, antibodies and other related immunotherapies, vaccines, antisense oligonucleotides and siRNAs, and diagnostic methods for various diseases.
Advising clients who are involved in contentious patent scenarios, Stephanie has handled a variety of third party submissions, protests, and post-grant proceedings before the United States Patent and Trademark Office (USPTO). She has worked on over 55 inter partes review, post grant review, and covered business method review proceedings before the Patent Trial and Appeal Board (PTAB).
In addition, Stephanie also advises clients on the management of their US patent office activity alongside other global patent activity. For example, she routinely consults with clients on European third party observations and oppositions, and has consulted with clients on post-grant challenges in other key jurisdictions, including Australia, China, and Japan.
Her clients include Regeneron Pharmaceuticals, Inc., Foundation Medicine, Inc., BioNTech SE, Akouos, Inc., Biogen, Helix Nanotechnologies, Sana Biotechnology, and Viridian Therapeutics.